通过调节药物输送系统的自组装行为制造的具有超分子网络结构的原蛋白/谷氨酸复合气凝
Chengfei Yue1, Ying Yang1, Canhui Jiang1
1State Key Laboratory of New Textile Materials and Advanced Processing Technologies, School of Textile Science and Engineering, Wuhan Textile University, Wuhan 430200, China.
Gels (Basel, Switzerland)
|December 24, 2025
概括
研究人员开发了一种新的原/谷氨酸复合物气凝,用于先进的伤口包裹. 这种材料提供持续的药物释放,增强的机械性能和静血能力,改善伤口愈合潜力.
科学领域:
- 生物材料科学 生物材料科学
- 材料工程 材料工程 材料工程
- 再生医学是一种再生医学.
背景情况:
- 具有持续药物释放的多功能伤口带对于感染控制和愈合至关重要.
- 原复合物气凝是有希望的,但缺乏机械强度和受控的药物释放.
研究的目的:
- 设计一种具有增强机械性能和持续药物释放的原复合气凝,用于伤口愈合应用.
- 利用谷氨酸来调节原体的自我组装,以提高气凝的性能.
主要方法:
- 采用了多个尺度的设计方法,使用谷氨酸 (Glu) 来控制原体的自我组装.
- 进行了结构和性能分析,以评估气凝的性能.
主要成果:
- 原/谷氨酸复合气凝表现出具有高密度原纤维的超分子网络结构.
- 气凝表现出优异的结构稳定性,优异的机械性能和持续的药物释放特性.
- 该材料显示出出色的生物相容性和静血能力.
结论:
- 开发的原/谷氨酸复合气凝为先进的伤口带提供了一个有前途的战略.
- 多尺度设计方法为创造超分子结构提供了新的见解,以实现持续的药物输送.
- 这些气凝显示出未来在伤口管理中的临床应用的巨大潜力.
更多相关视频
相关概念视频
Protein Complex Assembly
Proteins can form homomeric complexes with another unit of the same protein or heteromeric complexes with different types. Most protein complexes self-assemble spontaneously via ordered pathways, while some proteins need assembly factors that guide their proper assembly. Despite the crowded intracellular environment, proteins usually interact with their correct partners and form functional complexes.
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Oligosaccharide Assembly
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
Protein Folding Quality Check in the RER
ER is the primary site for the maturation and folding of soluble and transmembrane secretory proteins. The calnexin cycle is a specific chaperone system that folds and assesses the confirmation of N-glycosylated proteins before they can exit the ER lumen. The primary players of this quality check pipeline are the lectins, ER-resident chaperones, and a glucosyl transferase enzyme. In case the calnexin system in the lumen fails to salvage a misfolded protein, it is transported to the cytoplasm...
Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...


